(Q38002719)

26 August 2017

title

Molecularly targeted therapies in cervical cancer. A systematic review (English)

1 reference

26 August 2017

1 reference

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author

Theodoros N. Sergentanis

2

1 reference

26 August 2017

Flora Zagouri

1

1 reference

26 August 2017

Dimosthenis Chrysikos

3

1 reference

26 August 2017

Martin Filipits

4

1 reference

26 August 2017

Rupert Bartsch

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

11 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

126

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

291-303

1 reference

Global cancer statistics, 2002

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Cervical cancer screening policies and coverage in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Sarcomatoid variant of B-cell lymphoma of the uterine cervix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A prospective phase I–II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The ubiquitin-proteasome system meets angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Tumor angiogenesis: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The biology of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Prognostic value of vascular endothelial growth factor in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Vascular endothelial growth factor: basic science and clinical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Vascular endothelial growth factor and prognosis of cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Angiogenesis Modulators Expression in Culture Cell Lines Positives for HPV-16 Oncoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

mTOR and cancer: insights into a complex relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Expression of epidermal growth factor receptor in carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Gefitinib--a novel targeted approach to treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Trastuzumab for gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

HER2 protein (p185(HER2)) is only rarely overexpressed in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The significance of Erb-b2 immunostaining in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The role of mTOR in the management of solid tumors: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Activation of mTOR signaling pathway contributes to survival of cervical cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Systematic reviewers commonly contact study authors but do so with limited rigor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Targeted therapies for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

The role of targeted therapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Mechanism of ricin-induced apoptosis in human cervical cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.007

10.1016/J.YGYNO.2012.04.007

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference